Researchers identified blood lipid-associated adipose tissue methylation marks with an epigenome-wide association study on obese individuals undergoing bariatric surgery.
The in vitro diagnostic uses next-generation sequencing to detect clinically actionable genetic variants to guide therapy selection for cancer patients.
The company hopes to commercialize the assay, and is pursuing a larger validation study, but may face competitors who have also staked claims for this indication.
The company will launch a clinical version of its liquid biopsy assay in the second quarter and plans to launch clinical trials that make the case for reimbursement.
The company — a spinout of the New York Genome Center — said it will use the funding in part to develop its technologies for new applications in agriculture.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.
Researchers brought together blood transcriptomic, metabolomic, proteomic, and immune cell profiles for dozens of West African and Australasian infants.
The test will leverage next-generation sequencing to sequence PCR amplicons of the UL54 and UL97 genes in which drug resistance with CMV has been associated.
With single-cell RNA-seq on thousands of cells from the lateral hypothalamic area of male and female mice, researchers saw dozens of glutamatergic and GABAergic neuron types.
Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."
The researchers analyzed samples from 60 countries to find antimicrobial resistance gene levels correlated with economic, health, and environmental factors.
Analyzing mutational signatures in cancer cell lines and xenografts, investigators identified mutagenic processes that do or don't remain active in vitro.
